Suppressor of cytokine signalling-1 induces significant preclinical antitumor effect in malignant melanoma cells. (Q38853116)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26173926 AND SRC:MED&resulttype=core&format=json

19 February 2020

title

Suppressor of cytokine signalling-1 induces significant preclinical antitumor effect in malignant melanoma cells (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26173926 AND SRC:MED&resulttype=core&format=json

19 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26173926 AND SRC:MED&resulttype=core&format=json

19 February 2020

Minoru Fujimoto

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26173926 AND SRC:MED&resulttype=core&format=json

19 February 2020

Tetsuji Naka

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26173926 AND SRC:MED&resulttype=core&format=json

19 February 2020

7

Hiroyuki Murota

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26173926 AND SRC:MED&resulttype=core&format=json

19 February 2020

9

Ichiro Katayama

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26173926 AND SRC:MED&resulttype=core&format=json

19 February 2020

4

Atsushi Tanemura

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26173926 AND SRC:MED&resulttype=core&format=json

19 February 2020

6

Tomoharu Ohkawara

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26173926 AND SRC:MED&resulttype=core&format=json

19 February 2020

5

Rie Nakatsuka

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26173926 AND SRC:MED&resulttype=core&format=json

19 February 2020

author name string

Naoko Tagami-Nagata

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26173926 AND SRC:MED&resulttype=core&format=json

19 February 2020

Tadamitsu Kishimoto

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26173926 AND SRC:MED&resulttype=core&format=json

19 February 2020

publication date

3 September 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26173926 AND SRC:MED&resulttype=core&format=json

19 February 2020

published in

Experimental Dermatology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26173926 AND SRC:MED&resulttype=core&format=json

19 February 2020

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26173926 AND SRC:MED&resulttype=core&format=json

19 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26173926 AND SRC:MED&resulttype=core&format=json

19 February 2020

page(s)

864-871

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26173926 AND SRC:MED&resulttype=core&format=json

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.

19 February 2020

cites work

1 reference

The genome and epigenome of malignant melanoma

21 January 2018

1 reference

Understanding signaling cascades in melanoma

21 January 2018

1 reference

CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium

21 January 2018

1 reference

The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma

21 January 2018

1 reference

Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy.

21 January 2018

1 reference

Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies

21 January 2018

1 reference

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

21 January 2018

1 reference

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma.

21 January 2018

1 reference

6-Bromoindirubin-3'-oxime inhibits JAK/STAT3 signaling and induces apoptosis of human melanoma cells.

21 January 2018

1 reference

21 January 2018

1 reference

Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients

21 January 2018

1 reference

The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop

21 January 2018

1 reference

Structure and function of a new STAT-induced STAT inhibitor

21 January 2018

1 reference

A family of cytokine-inducible inhibitors of signalling

21 January 2018

1 reference

Cloning and characterization of novel CIS family genes

21 January 2018

1 reference

Three distinct domains of SSI-1/SOCS-1/JAB protein are required for its suppression of interleukin 6 signaling

21 January 2018

1 reference

A new protein containing an SH2 domain that inhibits JAK kinases

21 January 2018

1 reference

Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma

21 January 2018

1 reference

Aberrant methylation of suppressor of cytokine signalling-1 (SOCS-1) gene in pancreatic ductal neoplasms

21 January 2018

1 reference

Antiproliferative effect of SOCS-1 through the suppression of STAT3 and p38 MAPK activation in gastric cancer cells.

21 January 2018

1 reference

Molecular mechanism underlying the antiproliferative effect of suppressor of cytokine signaling-1 in non-small-cell lung cancer cells.

21 January 2018

1 reference

STAT3-mediated transcription of Bcl-2, Mcl-1 and c-IAP2 prevents apoptosis in polyamine-depleted cells

21 January 2018

1 reference

SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma

21 January 2018

1 reference

Suppressor of cytokine signaling 1 blocks mitosis in human melanoma cells.

21 January 2018

1 reference

Regulation and function of the p53 tumor suppressor protein

21 January 2018

1 reference

High-level expression of wild-type p53 in melanoma cells is frequently associated with inactivity in p53 reporter gene assays

21 January 2018

1 reference

MERTK receptor tyrosine kinase is a therapeutic target in melanoma.

21 January 2018

1 reference

Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73.

21 January 2018

1 reference

Melanoma proliferation and chemoresistance controlled by the DEK oncogene

21 January 2018

1 reference

Blinded by the Light: The Growing Complexity of p53

21 January 2018

1 reference

The genetics of malignant melanoma: lessons from mouse and man.

21 January 2018

1 reference

MDM4 is a key therapeutic target in cutaneous melanoma

21 January 2018

1 reference

DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2

21 January 2018

1 reference

Acetylation of lysine 382 and phosphorylation of serine 392 in p53 modulate the interaction between p53 and MDC1 in vitro

21 January 2018

1 reference

SOCS1 links cytokine signaling to p53 and senescence

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/EXD.12802

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26173926 AND SRC:MED&resulttype=core&format=json

19 February 2020

1 reference